$LPTX
LEAP THERAPEUTICS, INC.

2023 Q3 Form 10-Q Financial Statement

#000141057823001824 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.330M $3.560M
YoY Change 4.52% 24.69%
% of Gross Profit
Research & Development $11.50M $11.10M
YoY Change -4.95% -20.94%
% of Gross Profit
Depreciation & Amortization $0.00 $4.000K
YoY Change -100.0% 0.0%
% of Gross Profit
Operating Expenses $14.83M $14.66M
YoY Change -2.98% -13.24%
Operating Profit -$14.83M -$14.66M
YoY Change -2.98% -13.24%
Interest Expense $580.0K $970.0K
YoY Change 5172.73% 5605.88%
% of Operating Profit
Other Income/Expense, Net $550.0K $300.0K
YoY Change -15.64% -48.89%
Pretax Income -$13.70M -$13.39M
YoY Change -9.24% -21.35%
Income Tax
% Of Pretax Income
Net Earnings -$13.70M -$13.39M
YoY Change -9.26% -21.35%
Net Earnings / Revenue
Basic Earnings Per Share -$0.51 -$0.91
Diluted Earnings Per Share -$0.51 -$0.91
COMMON SHARES
Basic Shares Outstanding 25.57M 119.4M
Diluted Shares Outstanding 26.99M 14.71M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.70M $91.42M
YoY Change 3.05% 0.59%
Cash & Equivalents $80.74M $91.42M
Short-Term Investments
Other Short-Term Assets $300.0K $419.0K
YoY Change -19.79% -2.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $81.76M $93.88M
YoY Change 2.28% 1.56%
LONG-TERM ASSETS
Property, Plant & Equipment $9.000K $13.00K
YoY Change -62.5% -53.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $934.0K
YoY Change 1900.0% 1456.67%
Total Long-Term Assets $1.285M $1.977M
YoY Change -42.3% 12.2%
TOTAL ASSETS
Total Short-Term Assets $81.76M $93.88M
Total Long-Term Assets $1.285M $1.977M
Total Assets $83.05M $95.86M
YoY Change 1.07% 1.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.899M $6.500M
YoY Change -6.01% -13.94%
Accrued Expenses $4.770M $4.826M
YoY Change -5.39% 95.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.04M $11.76M
YoY Change -5.84% 12.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $38.00K
YoY Change -100.0% -91.98%
Total Long-Term Liabilities $0.00 $38.00K
YoY Change -100.0% -91.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.04M $11.76M
Total Long-Term Liabilities $0.00 $38.00K
Total Liabilities $11.04M $11.80M
YoY Change -8.72% 8.41%
SHAREHOLDERS EQUITY
Retained Earnings -$387.1M -$373.4M
YoY Change 26.48% 28.34%
Common Stock $26.00K $26.00K
YoY Change -73.74% -70.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $72.01M $84.06M
YoY Change
Total Liabilities & Shareholders Equity $83.05M $95.86M
YoY Change 1.07% 1.76%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$13.70M -$13.39M
YoY Change -9.26% -21.35%
Depreciation, Depletion And Amortization $0.00 $4.000K
YoY Change -100.0% 0.0%
Cash From Operating Activities -$10.48M -$10.19M
YoY Change -14.47% -16.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$348.0K
YoY Change
Cash From Investing Activities $0.00 -$348.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -10.48M -10.19M
Cash From Investing Activities 0.000 -348.0K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -10.48M -10.53M
YoY Change -14.47% -14.08%
FREE CASH FLOW
Cash From Operating Activities -$10.48M -$10.19M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-13390000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17024000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-55253000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27400000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14710375
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11324893
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13794605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11324893
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
dei Entity Central Index Key
EntityCentralIndexKey
0001509745
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25565414
CY2022 lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
609000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9902137
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37990
dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike St, Suite B1-1
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-0360
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LPTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25565414
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91415000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2023Q2 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2046000
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
419000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
351000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
93880000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
67950000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
467000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
669000
CY2023Q2 lptx Research And Development Incentive Receivable Noncurrent
ResearchAndDevelopmentIncentiveReceivableNoncurrent
563000
CY2022Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
576000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
934000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1108000
CY2023Q2 us-gaap Assets
Assets
95857000
CY2022Q4 us-gaap Assets
Assets
70353000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6500000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5657000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4826000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11762000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11225000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
38000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
262000
CY2023Q2 us-gaap Liabilities
Liabilities
11800000
CY2022Q4 us-gaap Liabilities
Liabilities
11487000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25565414
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9902137
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
26000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
457038000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
376896000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
414000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
128000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373421000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318168000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
84057000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95857000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70353000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11104000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14045000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50046000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21829000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3558000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2855000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7342000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5703000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14662000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
16900000
us-gaap Operating Expenses
OperatingExpenses
57388000
us-gaap Operating Expenses
OperatingExpenses
27532000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14662000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-16900000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57388000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27532000
CY2023Q2 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
1157000
CY2022Q2 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
39000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
2005000
lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
44000
CY2022Q2 us-gaap Interest Expense
InterestExpense
17000
us-gaap Interest Expense
InterestExpense
38000
CY2023Q2 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
298000
CY2022Q2 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
587000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
570000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
624000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-145000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-733000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-452000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-498000
CY2023Q2 lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
-38000
lptx Change In Fair Value Of Warrant Liability
ChangeInFairValueOfWarrantLiability
12000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13390000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17024000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55253000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27400000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14710375
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14710375
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11324893
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11324893
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13794605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13794605
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11324893
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11324893
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13390000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17024000
us-gaap Net Income Loss
NetIncomeLoss
-55253000
us-gaap Net Income Loss
NetIncomeLoss
-27400000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
59000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
519000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
286000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
361000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13331000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16505000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54967000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27039000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
98557000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
519000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1266000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17024000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
83318000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
361000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2470000
us-gaap Net Income Loss
NetIncomeLoss
-27400000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
83318000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
28329000
CY2023Q2 lptx Conversion Of Temporary Equity Into Permanent Equity Value
ConversionOfTemporaryEquityIntoPermanentEquityValue
67716000
CY2023Q2 lptx Adjustments To Additional Paid In Capital Reclassification Of Warrants To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
78000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
59000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1265000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13390000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
84057000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9805000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000
lptx Adjustments To Additional Paid In Capital Redemption Of Warrants
AdjustmentsToAdditionalPaidInCapitalRedemptionOfWarrants
29000
lptx Conversion Of Temporary Equity Into Permanent Equity Value
ConversionOfTemporaryEquityIntoPermanentEquityValue
67716000
lptx Adjustments To Additional Paid In Capital Reclassification Of Warrants To Equity
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsToEquity
78000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
286000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2575000
us-gaap Net Income Loss
NetIncomeLoss
-55253000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
84057000
us-gaap Profit Loss
ProfitLoss
-55253000
us-gaap Profit Loss
ProfitLoss
-27400000
lptx In Process Research And Development Costs Acquired In Connection With Acquisition Of Flame
InProcessResearchAndDevelopmentCostsAcquiredInConnectionWithAcquisitionOfFlame
29582000
us-gaap Depreciation
Depreciation
8000
us-gaap Depreciation
Depreciation
8000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
202000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
206000
us-gaap Share Based Compensation
ShareBasedCompensation
2575000
us-gaap Share Based Compensation
ShareBasedCompensation
2470000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-452000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-498000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
70000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-336000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
575000
lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
638000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-382000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
679000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-203000
lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-208000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-779000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-272000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22885000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23777000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
50362000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1393000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
48969000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
29000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
210000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-29000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-210000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-140000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-46000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25915000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24033000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91415000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
90883000
lptx Issuance Of Temporary Equity In Connection With Acquisition
IssuanceOfTemporaryEquityInConnectionWithAcquisition
67715000
lptx Reclassification Of Warrants From Liability To Equity
ReclassificationOfWarrantsFromLiabilityToEquity
78000
lptx Issuance Of Common Stock In Connection With Acquisition
IssuanceOfCommonStockInConnectionWithAcquisition
9805000
lptx Issuance Of Warrants For Purchase Of Common Stock In Connection With Acquisition
IssuanceOfWarrantsForPurchaseOfCommonStockInConnectionWithAcquisition
13000
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
928000
lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
609000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91415000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-373421000
us-gaap Net Income Loss
NetIncomeLoss
-55253000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91415000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2023Q2 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
2609000
CY2022Q4 lptx Research And Development Incentive Receivable Current And Noncurrent
ResearchAndDevelopmentIncentiveReceivableCurrentAndNoncurrent
2099000
CY2023Q2 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
298000
CY2022Q2 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
587000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
570000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
624000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
-2051000
CY2022 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
1064000
CY2022 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-77000
CY2022Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2099000
lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
570000
lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-60000
CY2023Q2 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2609000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Concentration of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the year ended December 31, 2022 or for the six months ended June 30, 2023.</p>
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
61135000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
61135000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62074000
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
61135000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2023Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2023Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.78
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-38000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12000
CY2023Q2 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2892000
CY2022Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2093000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
299000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1635000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4826000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2022 lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
609000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
467000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
474000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
114000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
112000
us-gaap Operating Lease Expense
OperatingLeaseExpense
228000
us-gaap Operating Lease Expense
OperatingLeaseExpense
220000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
226000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
268000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
494000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
474000
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5008139
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-38000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
12000
lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1191715
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35.94
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
858500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
37531
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.42
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2012684
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
22.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y14D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
959281
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
39.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M1D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2012684
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
22.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.66
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8602
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8270
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0357
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M8D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M8D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5027000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M15D
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13390000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-17024000
us-gaap Net Income Loss
NetIncomeLoss
-55253000
us-gaap Net Income Loss
NetIncomeLoss
-27400000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13390000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17024000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55253000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27400000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14710375
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11324893
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13794605
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11324893
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
1421768
CY2023Q2 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
1421768
lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2493048
CY2022Q2 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrants
2493048
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5884055
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4801270
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5884055
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4801270
CY2023Q2 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
525000

Files In Submission

Name View Source Status
0001410578-23-001824-index-headers.html Edgar Link pending
0001410578-23-001824-index.html Edgar Link pending
0001410578-23-001824.txt Edgar Link pending
0001410578-23-001824-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lptx-20230630.xsd Edgar Link pending
lptx-20230630x10q.htm Edgar Link pending
lptx-20230630xex31d1.htm Edgar Link pending
lptx-20230630xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
lptx-20230630_cal.xml Edgar Link unprocessable
lptx-20230630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lptx-20230630_lab.xml Edgar Link unprocessable
lptx-20230630_pre.xml Edgar Link unprocessable
lptx-20230630x10q_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending